MedTrace Logo

Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

NCT07530666 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-04-15

No results posted yet for this study

Summary

A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia

Conditions

Interventions

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks or once every 4 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks or once every 4 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks or once every 4 weeks intravenously injection

DRUG

DS010 injection

Once every 3 weeks or once every 4 weeks intravenously injection

Sponsors & Collaborators

  • Dartsbio Pharmaceuticals Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-10-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07530666 on ClinicalTrials.gov